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analysis, no prognostic factors were observed in terms of OS, PFS
and NRM. However, having an interval between diagnosis and
alloHCT >2 years was associated to decreased relapse risk
(18 months NRM: 7% vs 52%, p = 0.01). Thiotepa dose was not
signiﬁcantly associated to clinical outcomes.

at 1.3mg/m2 on day+1, 4 and 7. Tacrolimus and MMF were
started at day+5
Results: Seven patients were enrolled so far, ﬁve males and 2
females. Median age was 58 years (26-60). Donors were 3
brothers, 3 sons and 1 mother. Disease risk index was high in 3,
intermediate in 3 and low in 1. Three patients had AML, two had
ALL and MM, one had ALL and one had CML. CMV recipient
status was negative in one and positive in 6. Median HCT-CI was
3(1-4). Median CD34 and CD3 infused were 4.13 x10^6 and
1.7x10^8/ kg recipient respectively, all were cryopreserved
except 2. Four patients had CRS before Cy infusion with ASTCT
grade of 1. Six patients had grade 3 hypokalemia around day+
4-5. Five patients had grade 3 mucositis and 2 had grade 1. Four
patients had neutropenic fever and one patient had engraftment fever. Median neutrophils and platelets engraftment were
16 and 26 days respectively. Chimerism post SCT was > =99%
donor at day 30 for all patients. Six patients are off tacrolimus
with median time to be off it was 187.5 days. Five pts had
aGVHD with maximum grade of I in 3 patients, II in one patient
and III in one patient at a median 50days post SCT. None
developed early hematuria, four had late hematuria with highest
grade of 4. Two patients were positive for BK virus. One
patient had reactivation of CMV, 2 had EBV and one had
adenovirus, all resolved. Three pts had HHV6 that resolved. Of
the 5 patients who were evaluable, one developed moderate
chronic GVHD. So far the median time to follow up is 455 days
(70-1239) with relapse and subsequently death in one patient
who had high risk AML with 3 different inductions prior to SCT. .
At 1 year for 4 evaluable patients IgG were >400 mg/dl and
CD4 > 350 cells/ul.

Conclusions: In our series, RIC TBF allows efﬁcient disease
control at the expense of increased incidence of severe early
toxicities. Despite a higher NRM, OS was similar to other RIC
regimens used for lymphoid malignancies. This regimen could be
considered for ﬁt patients with high-risk lymphoid diseases.
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Background: Bortezomib (Bor) can inhibit the proliferation of
dendritic cells (DCs) and block the expression of co-receptors
CD80, CD86 and secretion of cytokines IL-12 and TNF-α and hence
the ability of DCs to activate T cells. We started a pilot study
incorporating the addition of bortezomib to post-transplant
cyclophosphamide (PTCY) in the setting of peripheral blood (PB)
HLA-haploidentical stem cell transplantation (Haplo-SCT).
Methods: This is a single center open label pilot study. Eligible
patients received Fludarabine Melphalan TBI 200 cGy as conditioning followed by haplo-SCT and PTCY. Bor was administered

Survival Probability
Conclusions: Cy2Bor3 post PB Haplo-SCT was well tolerated.
Although small number of patients and limited but encouraging
results so far. The trial is ongoing.
Clinical Trial Registry: ClinicalTrials.gov ID: NCT03850366.
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